Quarterly report pursuant to Section 13 or 15(d)

License Agreements - Additional Information (Detail)

v3.3.1.900
License Agreements - Additional Information (Detail)
 3 Months Ended 9 Months Ended
Dec. 15, 2015
USD ($)
Dec. 15, 2015
GBP (£)
Oct. 16, 2012
USD ($)
Feb. 29, 2016
USD ($)
Feb. 29, 2016
USD ($)
Feb. 29, 2016
GBP (£)
Jun. 30, 2016
USD ($)
Jun. 30, 2016
GBP (£)
Feb. 29, 2016
GBP (£)
May. 31, 2015
USD ($)
Commitments and Contingencies [Line Items]                    
License payment $ 915,000 £ 600,000                
Maximum contingent payment       $ 930,000 $ 930,000       £ 600,000  
Accrued license fees       $ 930,000 930,000         $ 930,000
Payment for litigation settlement         0          
Annual license fee         $ 450,000 £ 300,000        
Asset purchase, cash paid     $ 3,500,000              
Asset Purchase Agreement Aggregate Consideration Paying Period         10 years 10 years        
Accrued milestone payments                   $ 2,500,000
Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Royalty on every net sales       5.00% 5.00%       5.00%  
Development Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Asset Purchase Agreement Aggregate Consideration Paying Period         10 years 10 years        
Minimum annual license maintenance fees         $ 150,000          
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Payment to acquire other assets         1,500,000          
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Payment to acquire other assets       $ 1,000,000            
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Payment to acquire other assets         5,000,000          
Scenario, Forecast                    
Commitments and Contingencies [Line Items]                    
Maximum contingent payment             $ 930,000 £ 600,000    
Accrued license fees             $ 930,000      
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Payment to acquire other assets         $ 500,000          
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments                    
Commitments and Contingencies [Line Items]                    
Royalty on every net sales       7.50% 7.50%       7.50%